A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Plexium, Inc.
Acerand Therapeutics Limited
Eli Lilly and Company
Rondo Therapeutics
Nuvectis Pharma, Inc.
Astellas Pharma Inc
Elevation Oncology
Novartis
Nuvectis Pharma, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Carisma Therapeutics Inc
Astellas Pharma Inc
Astellas Pharma Inc
Pfizer
Advaxis, Inc.
Morphotek
AO GENERIUM
Adaptimmune
Sumitomo Pharma America, Inc.
Cantargia AB
Blueprint Medicines Corporation
Karyopharm Therapeutics Inc
Novartis
Daiichi Sankyo
Checkpoint Therapeutics, Inc.
Novartis
AbGenomics B.V Taiwan Branch
Novartis
Navidea Biopharmaceuticals
Celgene
Janssen Research & Development, LLC
UbiVac
Santa Maria Biotherapeutics
Sanofi
Sanofi
BioVex Limited
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Boehringer Ingelheim
Eli Lilly and Company
Enzon Pharmaceuticals, Inc.
Sunesis Pharmaceuticals
XOMA (US) LLC